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INTRODUCTION
Behçet’s disease (BD) is a chronic, multi-systemic im-
mune disorder with an unknown etiology, characterized 
by recurrent oral and genital aphthous ulcerations, ar-
thritis, and skin manifestations, with ocular, vascular, 
neurological, and gastrointestinal (GI) involvement [1,2]. 
The diagnosis of intestinal BD is based on GI symptoms 
in BD patients and typical intestinal ulcerative lesions 
documented by objective measures [3]. Although the 
GI symptoms can range from asymptomatic or mild 
abdominal discomfort to severe abdominal pain, in-
volvement of the GI tract often leads to severe morbidity 
and mortality [4]. Additionally, these patients can have 
further complications such as massive hemorrhage, fis-
tula, or bowel perforation [3,5]. Similar to inflammatory 
bowel disease (IBD), intestinal BD is accompanied by 
different clinical courses [6] with chronic continuous 
symptoms or repeated episodes of relapse and remis-
sion [7,8]. Along with proper intervention with surgical 
management, the appropriate use of medical therapy 
given the life-long duration of the disease is of great 
importance in the management of intestinal BD [9,10]. 
Empirical medical therapies include 5-aminosalicyl-
ic acids (5-ASAs), corticosteroids, immunomodulators 
such as azathioprine and 6-mercaptopurine (6-MP), 
thalidomide, and anti-tumor necrosis factor α (TNF-α) 
agents. Therefore, we will cover and review the current 
optimal medical treatment options and recent data rel-
evant to patients with intestinal BD. Furthermore, new 
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Behçet’s disease (BD) is a chronic, idiopathic, relapsing immune-mediated dis-
ease involving multiple organs, and is characterized by recurrent oral and genital 
ulcers, ocular disease, gastrointestinal ulcers, vascular diseases, and skin lesions. 
In particular, gastrointestinal involvement in BD is followed by severe complica-
tions, including massive bleeding, bowel perforation, and fistula, which can lead 
to significant morbidity and mortality. However, the management of intestinal 
BD has not yet been properly established. Intestinal BD patients with a severe 
clinical course experience frequent disease aggravations and often require recur-
rent corticosteroid and/or immunomodulatory therapies, or even surgery. How-
ever, a considerable number of patients with intestinal BD are often refractory to 
conventional therapies such as corticosteroids and immunomodulators. Recently, 
there has been a line of evidence suggesting that biologics such as infliximab and 
adalimumab are effective in treating intestinal BD. Moreover, new biologics tar-
geting proteins other than tumor necrosis factor α are emerging and are under 
active investigation. Therefore, in this paper, we review the current therapeutic 
strategies and new clinical data for the treatment of intestinal BD.
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treatment modalities that might have the potential to be 
developed as novel therapeutic agents in the near future 
will also be discussed.
PRINCIPLES OF APPROACH TO THE MANAGE-
MENT OF INTESTINAL BD
According to the 2008 European League Against Rheu-
matism (EULAR) guidelines, there are unfortunately no 
evidence-based treatment guidelines that can be rec-
ommended for the management of intestinal BD [11]. 
There are a few large, randomized and controlled trials 
of potential management for patients with intestinal 
BD. Therefore, the management of intestinal BD has 
been empirically based on the treatment guidelines for 
Crohn’s disease (CD) following opinions of expert phy-
sicians [2]. Correspondingly, according to the Japanese 
consensus of intestinal BD published in 2007, 5-ASAs, 
corticosteroids, immunomodulators, enteral nutrition, 
total parenteral nutrition, and surgical therapy were in-
cluded in standard therapy for intestinal BD [12]. In ad-
dition, in 2014, the 2nd edition of consensus statements 
for intestinal BD suggested that anti-TNF-α agents such 
as adalimumab and infliximab should be considered as 
standard therapy for intestinal BD [13]. Cheon and Kim 
[2] and Lee et al. [14] proposed a treatment algorithm for 
intestinal BD based on expert opinion and accumulated 
published data (Fig. 1).
MEDICAL TREATMENT
5-Aminosalicylic acids
5-ASAs can reduce inflammation and have immuno-
modulatory actions in the intestine [15]. 5-ASAs wide-
ly used for IBD are sulfasalazine and mesalamine [15]. 
Although evidence of efficacy in intestinal BD is still 
insufficient, the Japanese consensus statements recom-
mended 5-ASA as a first option for induction and main-
tenance therapy for mild or moderate intestinal BD [13]. 
5-ASA is usually administered at a dose of 2 to 4 g/day [2]. 
Sulfasalazine, a colon-selective drug that contains a sulfa 
group, is usually administered 3 to 4 g/day in intestinal 
BD [2].
In 1997, a case study reported that sulfasalazine use 
was associated with clinical improvement in 79% (11 of 
14, p < 0.005) of intestinal BD patients in Korea [16]. In 
contrast, Matsukawa et al. [17] reported the ineffective-
ness of 5-ASA in recurrent intestinal ulcers. However, 
Jung et al. [18] showed that 5-ASA/sulfasalazine therapy 
has a positive effect on maintaining remission in Ko-
rean patients with intestinal BD, although younger age 
(< 35 years), higher C-reactive protein (CRP) level, and 
higher disease activity were associated with a poor re-
sponse to 5-ASA/sulfasalazine. Another retrospective 
study on the effect of 5-ASA compounds reported that 
among 16 patients who were treated with 5-ASA com-
pounds, 62.5% (n = 10) achieved clinical remission with 
a disease-free duration of 89.3 ± 64.5 months (Table 1) 
[13,16,18-34]. This discrepancy between studies possibly 
originates from differences in disease heterogeneity, es-
pecially disease severity. 
Corticosteroids
Corticosteroids are fast-acting anti-inflammatory drugs 
that have been commonly used for patients with acutely 
moderate-to-severe and refractory intestinal BD [13,20-
22,35]. However, evidence on the efficacy of corticoste-
roids in intestinal BD also remains insufficient, because 
prospective/randomized studies are lacking. Treatment 
with corticosteroids is considered the first-line therapy 
during the acute phase of the disease, initially at doses 
of 0.5 to 1.0 mg/kg/day of prednisolone for 1 to 2 weeks 
with tapering by 5 mg each week and stoppage within 3 
months (Table 1) [2,36-38]. Prolonged use of predniso-
lone in excess of 10 mg/day is not recommended. Some 
Figure 1. A proposed algorithm for the treatment of intes-
tinal Behçet’s disease. Adapted from Lee et al. [14]. 5-ASA, 
5-aminosalicylic acid; anti-TNF, anti-tumor necrosis factor.
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Table 1. Studies of medical treatments of intestinal BD: 5-ASA, corticosteroids, immunomodulators, thalidomide, IVIG
Drugs Study Type of study
No. of 
patients or 
articles
Dose of medication Indication/Outcomes
5-ASA Yoo et al. 
(1997) [16]
Case report Total: 31
Sulfasala-
zine user: 
14
1 g/day → 2–4 g/day →  
1–2 g/day (maintenance)
Symptom improved: 79%
Sonta et al. 
(2000) [34]
Case report Total: 1 1,200 mg/day Lesion: esophageal ulcers
Positive clinical efficacy
Jung et al. 
(2012) [18]
Retrospective 
cohort study
Total: 292 - Maintaining remission; mild- 
to-moderate intestinal BD
Clinical remission: 143
Hisamatsu et 
al. (2014) [13]
Japanese 
consensus 
statements
Relevant 
articles: 15
5-ASA: 2.25–3.00 g/day
Sulfasalazine: 3–4 g/day
Indication: maintenance  
therapy
Hatemi et al. 
(2016) [19]
Retrospective 
cohort study
Total: 60
5-ASA user: 
16
- Remission: 10 of 16 patients 
(62.5%) 
Disease free duration: 
89.3 ± 64.5 months
Corticosteroids Nakase et al. 
(2001) [20]
Case report Total: 2 Case 1: PD 30 mg → 40 mg 
→ no improved: IV 2.5 mg 
dexamethasone every 2 
weeks
Case 2: PD 40 mg → 25 mg/
day → recur: IV 2.5 mg 
limethasone every 2 weeks
Case 1: after IV corticosteroid 
use, oral, abdominal pain 
improved & inflammatory 
parameters: normalized
Case 2: after IV corticosteroid 
use, abdominal symptoms 
disappeared & inflammatory 
parameters: normalized
Toda et al. 
(2002) [21]
Case report Total: 1 1 g/day of IV methylpred-
nisolone, 3 days → IV PD 
40 mg/day → 20 mg PD IA 
injection 
Disease remission
Yasuo et al. 
(2003) [22]
Case report Total: 1 PD 0.5 mg/kg daily Lesion: esophageal ulcer
Symptom improved &  
esophagoscopy after 4 weeks: 
mucosa healing 
Park et al. 
(2010) [23]
Retrospective 
cohort study
Total: 54 Median dosage: 0.58 mg/kg 
(range, 0.39–1.20)
Clinical remission: 25 (46.3%)
1 Year treatment response: 26 
(48.1%)
Cumulative probability of 
surgery: 17.5% at 1 year; 49.1% 
at 3 years
Hisamatsu et 
al. (2014) [13]
Japanese 
consensus 
statements
Relevant 
articles: 15
The initial dose of  
corticosteroids: 0.5–1  
mg/kg/day for 1–2 weeks 
Clinical improvement → 
tapered by 5 mg every week 
& stopped
Indication: induction therapy
Severe symptoms (i.e., abdominal 
pain, diarrhea, GI bleeding) 
Complications with deep  
ulcers confirmed by radiology 
or endoscopy
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Drugs Study Type of study
No. of 
patients or 
articles
Dose of medication Indication/Outcomes
Immunomodu-
lators
Choi et al. 
(2000) [24]
Retrospective 
cohort study
Total: 43 AZA: 50 mg/day Re-operation rates: decreased 
in AZA user group (7% vs. 
25% at 2 years; 25% vs. 47% at 
5 years) maintenance ther-
apy in patients who require 
surgery
Remission: 16 (38%)
Matsumura 
et al. (2010) 
[28] 
Case report Total: 1 Oral tacrolimus: 10–12 ng/mL 
(induction) → 5–10 ng/mL 
(maintenance)
Refractory case to 5-ASA, 
steroid, immunomodulators, 
thalidomide, infliximab
Remission: 33 months after 
starting tacrolimus
Jung et al. 
(2012) [26]
Retrospective 
cohort study
Total: 272
AZA user: 67 
(24.6%)
AZA: Initial dose 25 or 50 
mg daily → 2.0–2.5 mg/kg 
(gradually increased every 
2–4 weeks)
6-MP: Initial dose 0.5 → 
1.0–1.5 mg/kg (gradually 
increased)
Indication: maintenance  
therapy
Remission: 39 (58.2%) of 67 
(maintaining medically or 
surgically induced remission)
Clinical relapse: 13 (33.3%) of 39
Relapse risk factors: younger 
age (< 25 years) at diagnosis, 
lower hemoglobin level 
(< 11 g/dL) 
Hisamatsu et 
al. (2014) [13]
Japanese 
consensus 
statements
Relevant 
articles: 15
AZA: Initial dose 25–50  
mg/day
Indication: corticosteroid- 
dependent, corticosteroid- 
resistant, or anti-TNF-α 
mAb-resistant
Lee et al. 
(2015) [25]
Retrospective 
cohort study
Total: 77
Thiopurine 
user: 27 
(35.1%)
AZA: 2–2.5 mg/kg/day
6-MP: 1–1.5 mg/kg/day
Postoperative recurrence rate: 
lower in patients who  
received post-operative  
thiopurines than 5-ASA  
user (p = 0.050)
Park et al. 
(2015) [27]
Retrospective 
cohort study
Total: 196 
(IBD)
Intestinal 
BD: 83
AZA: 2–2.5 mg/kg/day
6-MP: converted to an  
equivalent AZA dose by 
multiplying by 2.08
Cumulative relapse-free 
survival rate: higher in the 
leukopenic group than in the 
non-leukopenic group  
(p < 0.001)
Hatemi et al. 
(2016) [19]
Retrospective 
cohort study
Total: 44 AZA Remission and no relapse: 24 
(65%)
Mean follow-up duration: 68.6 
± 43.6 months
Park et al. 
(2017) (un-
published 
data)
Retrospective 
cohort study
Total: 10
MTX mono-
therapy: 4
MTX + 
ADA: 6
MTX: various dose  
(subcutaneously & oral)
ADA: 160 mg in week 0, 80 
mg in week 2, and 40 mg 
every other week
Steroid free remission: 3  
patients (30%) at 3 months,  
4 patients (50%) at 6 months
CRP levels: significantly  
decreased at 6 months com-
pared with the baseline  
(p = 0.039).
Table 1. Continued
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case studies have reported the efficacy of an intravenous 
administration of a lipid emulsion of dexamethasone 
[20,21]. However, corticosteroid use was paradoxically 
associated with increased risk of GI bleeding and per-
foration [39]. Additionally, Park et al. [40] reported that 
corticosteroid use was significantly associated with 
re-bleeding in patients with intestinal BD. Despite 
these side effects, Park et al. [23] in 2010 performed a 
retrospective study of clinical outcomes after corticoste-
roid use in patients with moderate-to-severe intestinal 
BD. A total of 54 patients were enrolled and the medi-
an corticosteroid dosage was 0.58 mg/kg (interquartile 
range, 0.39 to 1.20). In this study, 46.3% of patients (n = 
25) achieved complete remission after 1 month of treat-
ment. Three months after treatment, 40.7% of patients 
(n = 22) showed treatment response. After 1 year, 48.1% (n 
= 26) remained responsive to treatment. However, after 
1 year, 35.2% of the patients (n = 19) exhibited cortico-
steroid dependency, and 7.4% (n = 4) received surgery. 
Treatment response at three months was independently 
associated with a decreased risk of surgery in the long 
term (p = 0.009). Therefore, the authors suggested that 
short-term response rate to initial corticosteroid ther-
apy was high in patients with intestinal BD [23]. Given 
Drugs Study Type of study
No. of 
patients or 
articles
Dose of medication Indication/Outcomes
Thalidomide Sayarlioglu et 
al. (2004) [32]
Case report Total: 1 100 mg/day Lesion: recurrent intestinal 
perforation cecum, transverse 
colon, terminal ileum
Remission: 4 months follow-up
Yasui et al. 
(2008) [31]
Case report Total: 7 Initial dose: 2 mg/kg/day → 
if necessary, 3 mg/kg/day 
(increase) or 1–0.5 mg/kg/
day (decreased) 
Inclusion case: conventional 
therapy failure, severe steroid 
toxicity 
Clinical improvement: all 
patients 
Lee et al. 
(2010) [33]
Case report Total: 4 Case 1: 200 mg/day
Case 2: 100 mg/day
Case 3: 100 mg/day
Case 4: 50 → 100 mg/day
Inclusion case: refractory to 
steroid, 5-ASA,  
immunomodulators
Clinical improvement: 3 of 4
IVIG Beales (1998) 
[30]
Case report 
(letters)
Total: 1 400 mg/kg/day for 5 days Lesion: oral, genital ulcer,  
uveitis, acneiform rash,  
arthralgia, intestine
Previous therapy: cyclosporine, 
 thalidomide maintenance → 
IV methyl PD, oral mesala-
mine add → no effect
Clinical improvement: after 30 
months 
Cantarini et 
al. (2016) [29]
Case report Total: 4
GI BD: 1
Case 3: 400 mg/kg/day for 5 
days per month
Lesion: mucocutaneous,  
ocular, neurological, GI
Previous therapy: prednisone, 
cyclosporine, AZA, mesalazine
Clinical improvement: after 14 
months
BD, Behçet’s disease; 5-ASA, 5-aminosalicylic acid; IVIG, intravenous immunoglobulin; PD, prednisolone; IV, intravenous; IA, 
intra-arterial; GI, gastrointestinal; AZA, azathioprine; 6-MP, 6-mercaptopurine; TNF-α, tumor necrosis factor α; mAb, mono-
clonal antibody; IBD, inflammatory bowel disease; MTX, methotrexate; ADA, adalimumab; CRP, C-reactive protein.
Table 1. Continued  
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this background, the Japanese consensus recommended 
that corticosteroids should be considered for induction 
therapy when patients have severe symptoms such as 
abdominal pain, diarrhea, or GI bleeding due to deep 
ulcers [13].
 
Immunomodulators
Immunomodulators included in this review are thiopu-
rines (6-mercaptopurine, 6-MP, and its prodrug azathi-
oprine), methotrexate, tacrolimus, interferon, cyclospo-
rin, and intravenous immunoglobuilin [41].
Thiopurines
Thiopurines are the most commonly prescribed immu-
nomodulators for patients with intestinal BD, especially 
those with moderate-to-severe disease and those who 
are corticosteroid-dependent/resistant or secondarily 
lose response to anti-TNF-α agents (Table 1) [1,2,13,24].
Thiopurine drugs such as azathioprine and 6-MP 
are also used in postoperative patients after intestinal 
resection to reduce the postoperative recurrence rate 
[25], and they were reported to be relatively useful in the 
maintenance of remission after surgery in intestinal BD 
patients [26]. The initial dose of azathioprine is 25 to 50 
mg/day, and if the azathioprine therapy is tolerated 
without side effects such as leukopenia and liver dys-
function, the dose can be gradually increased every 2 to 
3 weeks up to 2.0 to 2.5 mg/kg [13,26,42]. The dose for the 
initial use of 6-MP is 0.5 mg/kg, which can also be grad-
ually increased up to 1.0 to 1.5 mg/kg in a similar man-
ner to that of azathioprine [26]. Jung et al. [26] reported 
positive effects of thiopurine maintenance therapy in 
patients with intestinal BD in Korea. They retrospec-
tively evaluated patients with intestinal BD who received 
prolonged thiopurine monotherapy for over 6 months 
in a tertiary single center [26]. Of the 272 patients with 
intestinal BD, 67 patients (24.6%) received thiopurine 
therapy, and 39 of these 67 patients (58.2%) maintained 
medically or surgically induced remission. However, a 
younger age at diagnosis and a lower hemoglobin lev-
el were significantly associated with a poor response to 
thiopurines in this study [26]. 
Choi et al. [24] and Lee et al. [25] independently report-
ed the effects of postoperative thiopurine use in patients 
with intestinal BD (Table 1). Choi et al. [24] compared 
the reoperation rate between azathioprine users and 
non-users. Reoperation rates were significantly lower 
in azathioprine users (7%) than in non-users (25%) at 2 
years, and 25% and 47% at 5 years, respectively [24]. In ad-
dition, Lee et al. [25] investigated the postoperative pro-
tective effect of thiopurine. In their study, the postoper-
ative recurrence rate was significantly lower in patients 
who received postoperative thiopurines (p = 0.050) [25]. 
The most common side effect of thiopurine drugs was 
leukopenia, which is defined as a white blood cell (WBC) 
count lower than 3,000 or 4,000 cells/mm3 [26,27]. Fol-
lowing the American Gastroenterological Association 
recommendations, it is suggested that when patients 
are treated with azathioprine or 6-MP, routine laborato-
ry monitoring, including complete blood count, should 
be frequently performed [43]. Park et al. [27] reported that 
lower WBC count during thiopurine maintenance ther-
apy was associated with prolonged remission.
Methotrexate
The efficacy of other immunomodulators has also been 
reported. The use of methotrexate in patients with in-
testinal BD remains relatively poorly understood; how-
ever, Iwata et al. [44] reported the efficacy and safety of 
the combination of infliximab and methotrexate in 10 
patients with refractory intestinal BD. All the 10 patients 
had improved symptoms and disease-related complica-
tions within 4 weeks. In addition, 50% of the patients 
(five of 10) showed disappearance of ileocecal valve ulcers 
at 6 months, and 90% of the patients (nine of 10) showed 
disappearance of the ulcers at 12 months (Table 2) [44-
67]. Recently, Park et al. (unpublished data) also report-
ed the efficacy of methotrexate in patients with intes-
tinal BD as either mono- or combination therapy with 
adalimumab. In a retrospective review of 10 intestinal 
BD patients who received methotrexate treatment, four 
of the 10 patients received methotrexate monotherapy 
and the other six patients received combination therapy 
with adalimumab. In methotrexate monotherapy, three 
patients (30%) had steroid-free remission at 3 months, 
and four patients (50%) did at 6 months (unpublished 
data) (Table 1).
Tacrolimus
Oral tacrolimus is a macrolide antibiotic with potent 
immunosuppressive activity [68], and it is widely used 
for the prevention of allograft rejection in patients who 
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Table 2. Studies of medical treatment of intestinal BD: anti-TNF agents and biologics
Drugs Study Type of study
No. of  
patients
Dose of medication Outcomes
Infliximab Hassard et 
al. (2001) 
[53]
Case report Total: 1 5 mg/kg, at 0, 2, 7,  
and 23 weeks
Disease activity: CDAI 270 (baseline) →  
13 (at 2 weeks)
Remission: after 10 weeks
Travis et 
al. (2001) 
[55]
Case report Total: 2 Case 1: 3 mg/kg  
(dose reduced  
because of recent 
sepsis)
Case 2: 5 mg/kg
Case 1: CRP 72 mg/L → 45 (on steroids) → 
70 (sepsis) → 29 (on infliximab) → 12 
(12 weeks later)
Case 2: CRP 109 mg/L → 25 (on steroids) 
→ 73 (recur) → 53→ < 6 (on infliximab)
Kram et al. 
(2003) [61]
Case report Total: 1 5 mg/kg dose over a 
6-week period  
(3 infusions)
CRP 18.7 → normal (on infliximab) 
→ 22.5 mg/mL (relapse) → normal (on 
infliximab + MTX) 
Lee et al. 
(2007) [67]
Case report Total: 1 5 mg/kg CRP: 70 → 6.7 mg/L (on infliximab)
CDAI: 183 → 88 (on infliximab)
HBI: 10 → 2 (on infliximab)
Byeon et 
al. (2007) 
[56]
Case report Total: 1 5 mg/kg Lesion: unhealed anastomosis site, early 
recurrent ulcers after a distal  
ileocecectomy
Remission: on endoscopy at 15 days after 
the infliximab infusion
Ugras et 
al. (2008) 
[62]
Case report Total: 1 5 mg/kg at weeks  
0, 2, and 6
Remission: 7 months
Naganu-
ma et al. 
(2008) [54]
Case report Total: 6 5 mg/kg at 0, 2, 6 
weeks (induction) & 
every 8 weeks  
(maintain)
Clinical remission: 4 of 6 (induction), 4  
of 4 (maintain)
Surgery: 2 of 6 (case 5-ileum ulceration, 
case 6-ileum ulceration with internal 
fistula)
Maruyama 
et al. 
(2012) [63]
Case report Total: 1 5 mg/kg at 0, 2, and 6 
weeks (induction) & 
every 8 weeks 
(maintain)
Remission: 6 years
Iwata et al. 
(2011) [44]
Retrospective 
study
Total: 10 Infliximab (3 mg/kg  
at 0, 2, and 6 weeks  
& every 8 weeks) + 
MTX (3 mg/kg to 
200 mg)
Short-term response: improved clinical 
symptoms & decreased ESR, CRP within 
4 weeks 
Long-term response: remain remission 
at 6, 12, and 24 months 
Lee et al. 
(2013) [45]
Retrospective 
multicenter 
study
Total: 28 5 mg/kg at weeks 
0,2, and 6 & every 8 
weeks
Moderate to severe disease
Clinical response: 2 weeks (75%), 4 (64.3%), 
30 (50%), 54 (39.1%)
Clinical remission: 2 (32.1%), 4 (28.6%), 30 
(46.2%), 54 (39.1%)
Biological response rate: 2 (82.1%), 4 (57.1%), 
30 (53.8%), 54 (43.5%)
Sustained response: 15 (53.6%)
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Drugs Study Type of study
No. of  
patients
Dose of medication Outcomes
Kinoshi-
ta et al. 
(2013) [64]
Retrospective 
study
Total: 15 5 mg/kg at 0, 2 and 
6 weeks & every 8 
weeks 
Short-term response at week 10: 12 of 15 
(80%)
Clinical remission: 8 of 15 (53%)
Clinical response: 4 of 15 (27%)
Long-term response after 12 months: 7 of 
11 (64%)
Clinical remission: 3 of 11 (27%)
Clinical response: 4 of 11 (36%)
After 24 months: 4 of 8 (50%)
Clinical remission & response: 3 of 8 (38%)
Ideguchi et 
al. (2014) 
[65]
Retrospective 
study
Total: 43
Infliximab 
user: 7
- 1 of 7: remission
2 of 7: insufficient efficacy
1 of 7: AE, sepsis
2 of 7: unchanged
1 of 7: for concurrent rheumatoid  
arthritis
Hibi et al. 
(2016) [47]
Prospective, 
open-label,  
single-arm 
phase 3 study
Total: 18
Intestinal BD 
(11), NBD (3), 
VBD (4)
5 mg/kg at weeks 0, 2, 
6 (induction) & every 
8 weeks (maintain) 
until week 46
10 mg/kg (patients 
who showed inad-
equate responses 
after week 30)
Complete responder: 61% (11 of 18)
Intestinal BD: improvement in clinical 
symptoms & decrease in CRP levels 
after week 2
ADA De Cassan 
et al. 
(2011) [58]
Case report Total: 2 Induction dose of 160 
mg subcutaneously 
80 mg 2 weeks later
Maintenance: 40 mg 
every other week
Intestinal BD
Repeated steroid-dependent flares and 
failure of maintenance
Clinical response, remission: 1-year  
follow-up
Shimizu et 
al. (2012) 
[66]
Case report Total: 1 40 mg every other 
week
Lesion: marginal ulcer after surgery  
(total gastrectomy) in stomach
Improvement: after 3 months 
Tanida et 
al. (2015) 
[48]
Multicenter, 
open-label,  
uncontrolled 
study
Total: 20 160 mg at the start
80 mg at 2 weeks 
40 mg, every other 
week & 80 mg for in-
adequate response/
flare for 52 weeks
Intestinal BD
Symptom relief & endoscopic assessment 
scores of 1 or lower at week 24 of  
treatment: 9 of 20 (45%) 
At week 52: 12 patients (60%)
Tanida et 
al. (2016) 
[57]
Case report Total: 8 ADA: 160 mg in week 
0, 80 mg in week 2, 
40 mg every other 
week over 52 weeks
Refractory intestinal BD (failed to respond 
 to conventional treatments)
Primary outcome
MI: at 10 weeks; 5 of 8 (62.5%); at 52 weeks; 
6 of 8 (75%) 
Improvement of Global GI symptoms to 
score 0: at 10 weeks; 3 of 8 (37.5%); at 52 
weeks; 4 of 8 (50%)
Table 2. Continued
9Park YE and Cheon JH. Updated therapy for intestinal Behçet’s disease
www.kjim.orghttps://doi.org/10.3904/kjim.2017.377
Drugs Study Type of study
No. of  
patients
Dose of medication Outcomes
Vitale et al. 
(2017) [59]
Multicenter 
retrospective 
observational 
study
Total: 100 40 mg subcutane-
ously every 14 days 
(5 patients: initially 
treated with 40 mg 
every 7 days)
GI involvement: 47 of 100
At 12 weeks: ADA induced clinical efficacy 
in 81 patients
At 24 months: 67 of 100 patients were  
still on ADA therapy 
Combination therapy with DMARDs: no 
significantly superior to monotherapy
Inoue et al. 
(2017) [46]
Open label study 
following a 
phase 3 clinical 
trial
Total: 20
Study com-
pletion: 15
Initiated at 160 mg; 
2 weeks, 80 mg,  
followed by 40 mg  
every other week  
until the study end
Intestinal BD
Incidence of AEs through week 100; 544.4 
events/100 person-years
MI at weeks 52: 60.0%
MI at weeks 100: 40.0% 
CR at weeks 52: 20.0% 
CR at weeks 100: 15.0%
Etanercept Ma et al. 
(2014) [49]
Retrospective 
comparative 
study based on 
observation
Total: 54
Conventional 
therapy: 35
Etanercept: 
19
Etanercept,  
subcutaneously at  
the dose of 25 mg  
twice a week
Intestinal BD
Primary outcome: 4 criteria for diagnosis 
of BD
Remission rate, ulcer healing, recovery 
rate of ESR and CRP: significantly  
higher in Etanercept group than  
conventional group.
Less adverse reactions in intestinal BD: 
etanercept group 
ANA/CAN Cantari-
ni et al. 
(2015) [50]
Case report Total: 9 ANA, 100 or 150 mg/day 
With prednisone (5–25 
mg/day)
GI involvement BD: 3 of 9
On refractory to TNF blockers, standardized 
therapies 
Response to ANA: 8 of 9
Relapse: 8 of 9
Remain completely under control on 
ANA monotherapy: 1 patient
Emmi et 
al. (2016) 
[60]
Retrospective 
study
Total: 30
ANA: 27
CAN: 3 
ANA, 100 mg/day, 
subcutaneously
CAN, 150 mg,  
subcutaneously 
every 6–8 weeks
GI involvement BD: 13% (4 of 30)
CR at 12 months: 13 of 27
Maintain therapy: 6 of 13
Maintained the same drug: 1 of 6
Shifted from ANA to CAN: 6
AE: ANA, 4 of 27 (15%); CAN, 0 of 27
Vitale et al. 
(2014) [51]
Case report Total: 3 CAN, 150 mg  
every 6 weeks
Case 1: GI involve (+), symptom-free, 
6-month follow-up 
Case 2: GI involve (+), symptom-free, 
12-month follow-up
Case 3: GI involve (–), symptom-free, 
6-month follow-up
Table 2. Continued
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underwent organ transplantation [28]. Matsumura et al. 
[28] reported improvement after using tacrolimus in a 
patient refractory to conventional therapeutic agents 
such as 5-ASA, corticosteroids, immunomodulators, 
and infliximab. In our experience at Severance Hospital, 
four patients underwent tacrolimus therapy after failure 
of conventional agents, but none had a response to that 
drug (unpublished data).
Interferon
In 1957, Isaacs and Lindenmann [69] first introduced 
interferon (IFN), a large family of glycoproteins known 
to produce cellular responses to various antigens such 
as microbes, viruses, and tumors [70,71]. Several studies 
reported the efficacy of IFN alfa-2a in the treatment of 
BD, especially in patients with mucocutaneous lesions, 
arthritis, and ocular manifestations [70,72,73]. Alpsoy et 
al. [70] reported a randomized, placebo-controlled, and 
double-blind study in 50 patients with BD. Of the 50 
patients, 23 received IFN alfa-2a therapy, two of whom 
showed complete response while another 13 showed 
partial response. Eight patients showed no response. 
Grimbacher et al. [74] reported the efficacy of IFN al-
fa-2a in a patient who had eye and GI tract involvement. 
The patient experienced improved retinal infiltrates, 
skin lesions, and abdominal complaints within 2 weeks 
of treatment [74]. Monastirli et al. [75] presented a case 
demonstrating improvement of clinical symptoms in a 
patient who had intestinal BD and acute myelitis that 
were initially unresponsive to high-dose steroids; the pa-
tient remained drug-free until 12 months of follow-up. 
However, until now, there has been little research on the 
effect of IFN in patients with intestinal BD, and there-
fore it is difficult to clearly define the effect of IFN on 
intestinal BD.
Cyclosporin 
Cyclosporin is one of the most potent immunosuppres-
sive agents, which decreases T-cell activity and blocks 
the immune response of inflammatory cytokines [76]. 
Several studies reviewed the positive effect of cyclospo-
rin on the ocular manifestations of BD [11,77,78]. Fol-
lowing the EULAR guidelines, cyclosporin should not 
be used in BD patients with central nervous system in-
volvement [11]. With regard to intestinal BD, Bayraktar 
et al. [7] reported cyclosporin had no benefit on intesti-
nal BD. Therefore, further study is needed to clarify the 
efficacy of cyclosporin in intestinal BD.
Intravenous immunoglobulin 
Since 1952, immune globulin products from human 
plasma have been used to treat immune deficiency 
[29,79]. Intravenous immunoglobulin (IVIG) is an im-
munomodulating agent that has multiple activities and 
has been used for autoimmune and systemic inflamma-
tory diseases [29]. There are a limited number of studies 
regarding the role of the IVIG in intestinal BD. Beales 
[30] reported a case of IVIG treatment without addition-
al corticosteroids in a BD patient with colon involve-
ment after initial failed treatment with corticosteroids 
Drugs Study Type of study
No. of  
patients
Dose of medication Outcomes
Tocilizum-
ab
Deroux et 
al. (2015) 
[52]
Case report &  
literature  
review
Total: 15
Case: 4 
Literature re-
view related 
case: 11
8 mg/kg every 4 weeks 
or 2 weeks
Refractory BD
GI involvement: 3 of 4 (case)/1 of 11  
(literature)
In 4 cases: BD activity decreased  
significantly
In literature review (11 previous cases): 
8 of 11, improvement; 3 of 11, without 
efficacy
BD, Behçet’s disease; TNF, tumor necrosis factor; CDAI, Crohn’s Disease Activity Index; CRP, C-reactive protein; MTX, meth-
otrexate; HBI, Harvey-Bradshaw Index; ESR, erythrocyte sedimentation rate; AE, adverse event; BD, Behçet’s disease; NBD, 
neurological Behçet’s disease; VBD, vascular Behçet’s disease; ADA, adalimumab; GI, gastrointestinal; DMARD, disease modi-
fying anti-rheumatic drug; MI, marked improvement; CR, complete remission; ANA, anakinra; CAN, canakinumab. 
Table 2. Contued
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and other immunomodulators. She significantly im-
proved after IVIG initiation, and bowel lesions disap-
peared after 6 weeks. Cantarini et al. [29] reported suc-
cessful treatment with IVIG in patients with severe and 
resistant BD. Of four patients, all had mucocutaneous 
involvement with BD and one patient had intestine in-
volvement (Table 1) [29]. Therefore, the effect of IVIG on 
intestinal BD still warrants further study.
Thalidomide
Thalidomide, a synthetic derivative of glutamic acid, was 
first introduced in 1957 and used as a sedative agent with 
a teratogenic side effects; however, recent research has 
shown growing interest in its anti-inflammatory and 
immunomodulatory properties [2,31]. Therefore, there 
have been several studies of thalidomide treatment in 
pediatric patients with BD who were refractory to other 
immunomodulators, or those who developed undesir-
able side effects [80,81]. 
Sayarlioglu et al. [32] reported beneficial effects of tha-
lidomide on recurrent perforating intestinal ulcers in 
an adult patient with BD. Additionally, Yasui et al. [31] 
reviewed a case of thalidomide for the treatment of juve-
nile-onset intestinal BD, which included seven patients 
with severe and recurrent intestinal involvement. The 
initial dose of thalidomide was 2 mg/kg/day, with dose 
adjustment according to response; if necessary, the dose 
of thalidomide was increased up to 3 mg/kg/day or de-
creased to 0.5 to 1 mg/kg/day [31]. All the seven patients 
achieved clinical improvement and were allowed to stop 
corticosteroid therapy [31]. In Korea, Lee et al. [33] also 
reported the efficacy of thalidomide in four patients 
who had chronic relapse of intestinal BD that repeatedly 
required corticosteroids and was refractory to conven-
tional therapy such as 5-ASA and immunomodulators. 
Three of the four patients showed clinical symptom 
improvements; however, two of the four patients had to 
stop the therapy due to side effects such as general ede-
ma, leukopenia, and sepsis (Table 1). 
It has been reported that thalidomide reduces TNF-α 
levels via degradation of its encoding messenger RNA, 
and thus shows immunomodulatory effects [82]. Hatemi 
et al. [83] investigated 13 patients with intestinal BD who 
were refractory to conventional therapy were treated 
with anti-TNF-α and/or thalidomide. Of those, 10 pa-
tients (75%) achieved clinical and endoscopic remission 
[83]. Therefore, thalidomide may become a therapeutic 
option for intestinal BD, but it should be carefully se-
lected and monitored due to its teratogenicity and side 
effects such as edema, leukopenia, and sepsis. Further 
well-designed studies are necessary to conduct proper 
use.
Others
Colchicine
Colchicine is an anti-inflammatory drug that suppresses 
the secretion of cytokines and chemokines, and is used 
for the management of patients with gout and BD [35,84]. 
Some studies reported the improvement of arthralgia 
and erythema nodosum in patients with BD, but the 
effect on mucocutaneous manifestations was contro-
versial in several studies [85-87]. Therefore, the EULAR 
recommended that colchicine is preferred when the 
dominant lesion is erythema nodosum [11]. However, 
currently, there is no evidence on the use of colchicine 
for intestinal BD. Choi et al. [24] suggested that there 
are no beneficial effects on intestinal lesions from their 
retrospective study. There is an insufficient number of 
studies to prove efficacy of colchicine in intestinal BD.
Stem cell transplantation and leukocytapheresis
Hematopoietic stem cell transplantation (HSCT) has 
been used to treat severe autoimmune and inflamma-
tory conditions that are unresponsive to traditional 
therapies [38,88]. HSCT in patients with BD has been 
reported several times in forms of case reports either for 
refractory BD or patients with associated hematological 
conditions such as aplastic anemia or myelodysplastic 
syndrome (MDS) [88-90]. This treatment is based on the 
rationale that a vigorous immunoablative regimen can 
remove autoaggressive lymphocyte clones [2]. Yamato 
[89] and Rossi et al. [90] reported cases of successful stem 
cell transplantation for MDS with BD and severe/refrac-
tory BD. HSCT could be an alternative therapy in BD 
patients with severe organ involvement, including GI 
involvement, that is refractory to immunomodulators 
[88]. Allo-stem cell transplants have high transplant-re-
lated morbidity and mortality; therefore, autologous 
transplants have been performed more frequently in 
BD patients, and non-myeloablative regimens may be 
preferred over myeloablative ones [88].
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According to the Japanese consensus statements for in-
testinal BD in 2014 [13], leukocytapheresis was classified 
into an experimental treatment to mechanically remove 
WBCs in patients with intestinal BD who are steroid-de-
pendent or resistant [2]. This is because activated neu-
trophils in patients with severe intestinal BD increase 
leukocytosis or cytokines [91]. However, this procedure 
also warrants further well-designed studies [2].
Anti-TNF-α agents and biologics
Intestinal BD is associated with abnormal T-cell im-
mune response and T helper type 1-associated cytokines 
such as TNF-α, IFN-γ, interleukin-12 (IL-12), and IL-18, 
which play a critical role in disease pathogenesis [92,93]. 
In patients with BD, the number of γδ cells producing 
TNF-α increases, TNF-α and its receptor levels are ele-
vated in the blood, and the expression of TNF-α increases 
when the clinical course becomes worse [93]. Therefore, 
the importance of anti-TNF-α agents has been report-
ed in several studies based on this background (Table 2) 
[45,46,67,94-97]. According to the Japanese consensus [13], 
anti-TNF-α mAbs (infliximab and adalimumab) should 
be considered as the standard therapy in patients with 
intestinal BD [2,13]. Infliximab is a chimeric monoclonal 
antibody against TNF-α [2] that can be considered for 
induction therapy with 5 mg/kg at 0, 2, and 6 weeks [13]. 
Responders should be administered maintenance ther-
apy with infliximab every 8 weeks [13]. Adalimumab is a 
fully human anti-TNF-α monoclonal antibody [48], and 
can also be used for induction therapy with a dose of 160 
mg at week 0 (baseline), 80 mg at week 2, and 40 mg at 
week 4 subcutaneously. Responders should be consid-
ered for maintenance therapy every other week at a dose 
of 40 mg [13]. In addition, several studies on the effects 
of various biologics such as etanercept, anakinra, canak-
inumab, and tocilizumab have been conducted [49-52].
Infliximab
Hassard et al. [53] reviewed a patient with chronically 
active, steroid-dependent intestinal BD who received 
4 doses of infliximab during 6 months. The patient 
achieved remission, with a reduced Crohn’s Disease 
Activity Index score (from 270 to 13) at 2 weeks of in-
fliximab use, and maintained remission after 10 weeks 
(Table 2) [53]. Naganuma et al. [54] also reported on the 
efficacy of infliximab induction and maintenance ther-
apy. Four of six patients with intestinal BD achieved 
remission, and all four patients maintained remission 
with infliximab therapy (Table 2) [54]. In 2013, Lee et 
al. [45] reported a multicenter retrospective study of 28 
patients with active moderate-to-severe intestinal BD 
who had been treated with infliximab at eight tertiary 
hospitals in Korea. At 2, 4, 30, and 54 weeks post-inflix-
imab infusion, patients showed clinical response rates 
of 75%, 64.3%, 50%, and 39.1%, and clinical remission 
rates of 32.1%, 28.6%, 46.2%, and 39.1%, respectively. In 
addition, independent factors of maintenance response 
were older age at diagnosis (≥ 40 years), female sex, a lon-
ger disease duration (≥ 5 years), concomitant immuno-
modulator use, and achievement of remission at week 
4 on multivariate analysis (Table 2) [45]. In a prospective 
open-label, single-arm phase 3 study in Japan, 18 pa-
tients with BD were enrolled, including 11 patients with 
intestinal BD, three patients with neurological BD, and 
four patients with vascular BD with poor response or 
resistance to conventional therapy [47]. Induction inflix-
imab therapy was administered at 5 mg/kg at weeks 0, 2, 
and 6, with maintenance therapy every 8 weeks thereaf-
ter until week 46. Eleven of 18 of the patients (61%) were 
complete responders at weeks 14 and 30 and remained 
in remission until week 54. In addition, laboratory find-
ings such as CRP levels were diminished, and 80% of 
patients showed healing or scarring ulceration at week 
14. However, three patients with intestinal BD had to in-
crease the dose of infliximab up to 10 mg/kg after week 
30 due to loss of response, and two of three patients had 
symptoms that could not be controlled and worsened 
(Table 2) [47]. 
The efficacy of infliximab induction and maintenance 
therapy for intestinal BD has been widely accepted in 
many studies [13,47,55]. However, there is still insuffi-
cient evidence on the effect of combination therapy with 
immunomodulators as well as whether it can be used 
as a postoperative therapy in patients who underwent 
bowel resection. Byeon et al. [56] reviewed a patient with 
an unhealed postoperative anastomotic site and recur-
rent ulcers after a distal ileocecectomy, and reported 
endoscopic remission after 15 days of infliximab infu-
sion. Iwata et al. [44] reported that concomitant therapy 
of infliximab with methotrexate was effective to achieve 
short-term remission and long-term response until 24 
months. Well-designed further studies are needed.
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Adalimumab
Adalimumab is a humanized anti-TNF-α monoclonal 
antibody [98] and is widely used in patients with rheu-
matoid arthritis (RA), psoriatic arthritis, ankylosing 
spondylitis, psoriasis, juvenile idiopathic arthritis, uve-
itis, and IBD [48,57,99]. In 2011, De Cassan et al. [58] first 
reported adalimumab efficacy in patients with intestinal 
BD with repeated steroid-dependent flares and failure of 
conventional therapy. After that, several studies showed 
the efficacy of adalimumab in patients with intestinal 
BD. Tanida et al. [48] performed a multicenter, open-la-
bel, uncontrolled study of adalimumab for the treat-
ment of Japanese patients with intestinal BD who were 
refractory to conventional therapy, including corticoste-
roids and/or immunomodulators. A total of 20 patients 
with intestinal BD were treated with adalimumab with 
dose of 160 mg at induction, 80 mg 2 weeks later, and 40 
mg every other week for 52 weeks; for some patients with 
incomplete response, the dose of adalimumab increased 
up to 80 mg every other week. After 24 weeks of adalim-
umab therapy, nine of 20 patients (45%) had alleviated 
GI symptoms and diminished endoscopic assessment 
scores to 1 or lower than at pre-treatment. In addition, 
12 of 20 patients (60%) had reduced endoscopic assess-
ment scores at week 52. Additionally, no newly discov-
ered safety problems or deaths were reported (Table 2) 
[48]. Recently, Inoue et al. [46] published an open-label 
phase 3 study (NCT01243671) in Japan to evaluate the 
safety and efficacy of adalimumab for the treatment of 
the same patients included in the 52 week follow-up 
study from weeks 52 to 100. Long-term efficacy of adali-
mumab was assessed on the basis of marked improve-
ment, defined as both a GI symptom score of ≤ 1 (did 
not affect patient’s daily life) and an endoscopic score 
of ≤ 1 (largest ulcer is ≤ 1/4 original size), and complete 
remission, defined as a GI symptom score of 0 (symp-
tom-free) and an endoscopic score of 0 (complete ulcer 
healing). At weeks 52 and 100, 12 of 20 patients (60%) and 
eight of 20 patients (40%) showed marked improvement, 
while four of 20 patients (20%) and three of 20 patients 
(15%) showed complete remission, respectively (Table 2) 
[46]. In addition, Kimura et al. [95] reported that a patient 
with intestinal BD and MDS successfully improved in 
GI symptoms, CRP levels, leukocytopenia, and anemia 4 
months after starting adalimumab.
Combination therapy with adalimumab and immu-
nomodulators has not yet been established, but Vitale 
et al. [59] conducted a multicenter retrospective study 
with 100 BD patients for the comparison of adalimum-
ab monotherapy and combination therapy with disease 
modifying anti-rheumatic drugs. Although the study 
was not limited to patients with intestinal BD, it did 
not show a significant difference in clinical outcomes 
between adalimumab monotherapy and combination 
therapy (Table 2) [59].
Etanercept
Etanercept is a dimeric human TNF receptor (TNFR) 
p75-Fc fusion protein that inhibits TNF-α activity 
[100,101]. Only a few studies have focused on etanercept 
as a treatment option for intestinal BD [49]. Ma et al. 
[49] reported on the outcomes of etanercept in the treat-
ment of intestinal BD with 19 patients who were refrac-
tory to conventional therapy. Etanercept (25 mg twice 
a week for 3 months) was compared with conventional 
therapy, and the etanercept group showed significantly 
greater healing of ulceration, remission, and recovery of 
the erythrocyte sedimentation rate and CRP levels [49]. 
However, etanercept was not effective for the treatment 
of IBD, unlike other anti-TNF agents such as inflix-
imab and adalimumab [102,103]. Sandborn et al. [102] 
conducted a randomized, double-blind, placebo-con-
trolled trial in patients with active CD using etanercept. 
Forty-three patients were enrolled; however, 39% of the 
etanercept-treated patients had a clinical response com-
pared with 45% of the placebo group (p = 0.763) at week 4 
[102]. Furthermore, some recent studies have suggested 
a paradoxical development of IBD in patients receiving 
etanercept therapy. Forty-four (41 CD, three ulcerative 
colitis [UC]) of 443 cases (297 CD, 146 UC) were report-
ed to develop de novo IBD after the initiation of etaner-
cept, and 43 cases of flares of existing IBD patients were 
reported in association with etanercept therapy [104]. 
Therefore, the therapeutic efficacy of etanercept in pa-
tients with intestinal BD is also questionable.
Anakinra
Anakinra is a recombinant version of the IL-1 receptor 
antagonist (IL1-RA) and a biologic agent used to modi-
fy the immune response of IL-1 [105]. Although the ex-
act etiology of BD is still unclear, it has been reported 
that IL-1 is a proinflammatory cytokine [106] which can 
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be increased in patients with BD. Zou and Guan [106] 
reported increased susceptibility to BD due to poly-
morphisms in the IL-1-related gene. Cantarini et al. 
[50] reported on the effects of anakinra in patients with 
conventional therapy-resistant BD. Nine patients were 
refractory to anti-TNF agents and conventional therapy, 
and most of them received anakinra (100 mg daily) with 
low doses of corticosteroids. Eight of nine patients had 
symptom improvement after using anakinra; however, 
the eight had recurrence over time and 15% of patients 
experienced adverse events (AEs) [50]. Although the ef-
ficacy of anakinra has been shown in a few studies, the 
long-term effect is unclear and most of the studies were 
not limited to patients with intestinal BD; therefore, 
more studies are required to clarify the relationship 
between recurrence and dosage, and to determine the 
exact efficacy in intestinal BD.
Canakinumab
Canakinumab is a fully human anti-IL-1β antibody which 
could also be considered as a therapeutic option for re-
sistant or refractory BD [51,60]. Vitale et al. [51] reported 
successful use of canakinumab in three patients with 
BD. Two patients had GI involvement and had failed to 
respond to conventional therapy such as sulfasalazine, 
methotrexate, cyclosporin, azathioprine, corticosteroids, 
anti-TNF agents, and anakinra (100 mg/day). Therefore, 
canakinumab was used at a dose of 150 mg every 6 (case 2) 
and/or 8 weeks (case 1) by subcutaneous injection, which 
led to clinical improvement and achieved clinical remis-
sion [51]. Recently, Emmi et al. [60] reported outcomes 
on the use of IL-inhibitors including canakinumab in 
patients with BD. Three patients used canakinumab (150 
mg every 6 to 8 weeks for 12 months) and achieved com-
plete remission at 12 months with no serious AEs (Table 
2) [60]. However, the study was not limited to intestinal 
BD. Therefore, further studies are required.
Tocilizumab
Tocilizumab is a recombinant-humanized anti-human 
IL-6 receptor monoclonal antibody [107]. IL-6 is a cyto-
kine that plays an important role in immune function, 
and some studies have shown that circulating IL-6 level 
is elevated in patients with BD [52,108]. Deroux et al. [52] 
reported four experienced cases using tociliziumab and 
reviewed the cases in the literature to evaluate the safety 
and efficacy of tocilizumab in patients with refractory 
BD. Three of the four patients were BD patients with 
GI involvement and all patients were previously unre-
sponsive to conventional therapy. All patients received 
tocilizumab (8 mg/kg every 4 weeks) and experienced 
significantly decreased disease activity [52]. However, to-
cilizumab failed in clinical trials for patients with CD 
because of serious adverse effects such as bowel perfora-
tion and abscess [109,110]. This is because IL-6 is known 
to play an important role in stimulating intestinal epi-
thelial proliferation and repairing intestinal injury [111]. 
Therefore, we should pay attention to the use of tocili-
zumab in patients with intestinal BD in whom intestinal 
perforation is one of the important complications, and 
further studies are required. 
CONCLUSIONS
Although intestinal BD is not common, GI manifestation 
occurs more frequently in East Asia, including Korea, 
than in the Mediterranean region [2,36,112,113]. In addi-
tion, complications such as intestinal perforation and 
bleeding considerably increase morbidity and mortality 
[2,3]; therefore, it is important to manage and treat pa-
tients properly. Appropriate medical therapy in intestinal 
BD is important to prevent poor outcomes such as fre-
quently recurred ulcer, surgery, complications, and mor-
tality. 5-ASA, corticosteroids, immunomodulators, and 
anti-TNF agents have been proposed as standard therapy 
in intestinal BD. However, there is still no definite guide-
line for established medical therapy because of its rari-
ty and lack of clinical data. Studies on the pathogenesis 
of BD have been carried out, and studies on new thera-
pies such as the therapeutic effects of related biological 
agents have been actively under investigation. We antici-
pate more advanced treatment strategies and established 
treatment guidelines in intestinal BD in the near future.
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